(Q36206628)

12 August 2017

1 reference

title

Phosphodiesterase type 5 inhibitors for erectile dysfunction (English)

1 reference

12 August 2017

Culley C Carson

1

1 reference

PubMed ID

16042713

12 August 2017

Tom F Lue

series ordinal

2

1 reference

12 August 2017

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

96

1 reference

12 August 2017

3

1 reference

12 August 2017

257-280

1 reference

The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Erectile physiological and pathophysiological pathways involved in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Age decreases nitric oxide synthase-containing nerve fibers in the rat penis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Hypertension is associated with severe erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Time course of the interaction between tadalafil and nitrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Effects of grapefruit juice on the pharmacokinetics of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Effect of sildenafil on nocturnal erections of potent men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Sildenafil citrate after radical retropubic prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic Prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Erectile dysfunction in the 21st century: whom we can treat, whom we cannot treat and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Evaluation of vardenafil and sildenafil on cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Summary of the recommendations on sexual dysfunctions in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05614.X

10.1111/J.1464-410X.2005.05614.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16042713